| Literature DB >> 29774990 |
Marta Gonzalez-Freire1, Fatemeh Adelnia1, Ruin Moaddel2, Luigi Ferrucci1.
Abstract
Sarcopenia, the age-related loss of muscle mass and strength, is linked to a range of adverse outcomes, such as impaired physical performance, cognitive function, and mortality. Preventing sarcopenia may reduce the burden of functional decline with aging and its impact on physiological and economic well-being in older adults. Mitochondria in muscle cells lose their intrinsic efficiency and capacity to produce energy during aging, and it has been hypothesized that such a decline is the main driver of sarcopenia. Oxidative phosphorylation becomes impaired with aging, affecting muscle performance, and contributing to an age-associated decline in mobility. However, it is unclear whether this deterioration is due to a reduced mitochondria population, decreased mitochondrial energetic efficiency, or a reduced capacity to dynamically transport oxygen and nutrients into the mitochondria, and addressing these questions is an active area of research. Further research in humans will require use of new "omics" technologies, progress in neuroimaging techniques that permit energy production assessment, and visualization of molecules critical for energetic metabolism, as well as proxy biomarkers of muscle perfusion. Published 2018. This article is a U.S. Government work and is in the public domain in the USA.Entities:
Keywords: Aging; Branched chain amino acids; Mitochondria; Muscle quality; Sarcopenia; Skeletal muscle
Mesh:
Year: 2018 PMID: 29774990 PMCID: PMC5989834 DOI: 10.1002/jcsm.12313
Source DB: PubMed Journal: J Cachexia Sarcopenia Muscle ISSN: 2190-5991 Impact factor: 12.910
Figure 1Low muscle quality is characterized by impaired transport of amino acids, especially branched chain amino acids. (A) Metabolomics plasma metabolites are ordered by expression differences between age, sex, and height matched pairs of cases (low muscle quality) and controls (high muscle quality) from the Baltimore Longitudinal of Aging. Participants with low muscle quality presented higher plasma concentrations of most amino acids, particularly isoleucine and leucine, compared with the control group (adapted from Moaddel et al.8) (N= 79 cases and 79 controls). (B) Concentration of BCAAs in biopsy specimens collected from the vastus lateralis was lower in participants with low muscle quality compared with those with high muscle quality (unpublished results) (N= 9 cases and 9 controls). ILE, isoleucine; LEU, leucine; VAL, valine; BCAA, branched chain amino acids.